Michael A. Gold
Expertise in
20
conditions

Dr. Michael A. Gold

Obstetrics and Gynecology
12697 E 51st St, 
Tulsa, OK 
Accepting New Patients
Expertise in
20
conditions
12697 E 51st St, 
Tulsa, OK 

Overview

Michael A. Gold, MD, is a board-certified, independent gynecologic oncologist at Ascension St. John in Tulsa, Oklahoma. Dr. Gold diagnoses and treats women's reproductive cancer affecting the cervix, uterus and ovaries and vulva.

Dr. Gold is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Lymphadenectomy, and Bladder Reconstruction.

Dr. Gold is board certified in The American Board Of Obstetrics And Gynecology - Gynecologic Oncology and The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. He is actively involved in clinical research, co-authoring 47 peer reviewed articles and participating in 11 clinical trials. Dr. Gold is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in OK

Board Certifications

The American Board Of Obstetrics And Gynecology - Gynecologic Oncology
The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology

Fellowships

University of Oklahoma Health Sciences Center

Hospital Affiliations

Ascension St. John Medical Center
Hillcrest Medical Center
Ascension St John Medical Center
Saint Francis Hospital, Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
CommunityCare
  • HMO
GlobalHealth
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Oklahoma Cancer Specialist and Research Institute
12697 E 51st St, Tulsa, OK 74146

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Terminated
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 24, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 28, 2025
Intervention Type: Biological
Study Drug: AK104
Study Phase: Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drug: Prexasertib
Study Phase: Phase 2
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

47 Total Publications

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.
Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.
Journal: Future oncology (London, England)
Published: April 07, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Katherine M. Moxley
Obstetrics and Gynecology
Expertise in
14
conditions
Dr. Katherine M. Moxley
Obstetrics and Gynecology
Referral may be required

Oklahoma Cancer Specialist And Research Institute

12697 E 51st St, 
Tulsa, OK 
 (0.1 miles away)
918-505-3200
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Katherine M. Moxley, MD, MS, is a board-certified, independent obstetrician and gynecologist (OB-GYN) and gynecologic oncologist at Ascension St. John in Tulsa, Oklahoma. She listens to understand you and your preferences as a woman. Then Dr. Moxley works with you to deliver compassionate, personalized prenatal care throughout pregnancy, labor, and delivery. Dr. Moxley is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Gastrostomy. Dr. Moxley is board certified in The American Board Of Obstetrics And Gynecology - Gynecologic Oncology and The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. Dr. Moxley is currently accepting new patients.

Expertise in
15
conditions
Dr. Eric D. Thomas
Obstetrics and Gynecology
Expertise in
15
conditions
Dr. Eric D. Thomas
Obstetrics and Gynecology
Referral may be required

Oklahoma Cancer Specialist And Research Institute

12697 E 51st St, 
Tulsa, OK 
 (0.1 miles away)
918-505-3200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eric D. Thomas, MD, is a board-certified, independent obstetrician and gynecologist (OB-GYN) and gynecologic oncologist at Ascension St. John in Tulsa, Oklahoma. He listens to understand you and your preferences as a woman. Then Dr. Thomas works with you to deliver compassionate, personalized prenatal care throughout pregnancy, labor, and delivery. Dr. Thomas also specializes in female reproductive health conditions, menopause care, emotional health, breast health and more. Dr. Thomas is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Oophorectomy, and Bladder Reconstruction. Dr. Thomas is board certified in The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. Dr. Thomas is currently accepting new patients.

Expertise in
14
conditions
Dr. Rachel L. Gibbs
Obstetrics and Gynecology
Expertise in
14
conditions
Dr. Rachel L. Gibbs
Obstetrics and Gynecology
Referral may be required

Warren Clinic Gynecology

6465 South Yale Avenue, Suite 605, 
Tulsa, OK 
 (4.9 miles away)
918-502-4040
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Dr. Gibbs is a board certified gynecologist who specializes in minimally invasive gynecologic surgery. Dr. Gibbs is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Uterine Prolapse, Female Genital Sores, Rectocele, Vitiligo, and Hysterectomy. Dr. Gibbs is currently accepting new patients.

Frequently Asked Questions about Dr. Michael A. Gold

How do I make an appointment with Dr. Michael A. Gold?

You can book an appointment with Dr. Michael A. Gold by calling their office at 918-505-3200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael A. Gold a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael A. Gold is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael A. Gold specialize in?

While Dr. Michael A. Gold is a Obstetrics and Gynecology, they have specific expertise in Endometrial Cancer, Cervical Cancer, and Vulvar Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Michael A. Gold participate in research or clinical trials?

Yes. Dr. Michael A. Gold has published 47 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Michael A. Gold's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael A. Gold accept my insurance?

Dr. Michael A. Gold accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 918-505-3200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gold's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 7 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile